Drug
BEA 2180 BR
BEA 2180 BR is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 6 completed trials
Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
17%(1 trials)
Phase Distribution
Ph phase_1
2
33%
Ph phase_2
4
67%
Phase Distribution
2
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
6 of 6 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(6)
Detailed Status
Completed6
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (33.3%)
Phase 24 (66.7%)
Trials by Status
completed6100%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_2
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
NCT00528996
completedphase_2
Dose Finding Study in COPD
NCT00122434
completedphase_1
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects
NCT02263976
completedphase_1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers
NCT02254122
completedphase_2
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
NCT02242279
Clinical Trials (6)
Showing 6 of 6 trials
NCT00528996Phase 2
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
NCT00122434Phase 2
Dose Finding Study in COPD
NCT02263976Phase 1
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects
NCT02254122Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers
NCT02242279Phase 2
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
NCT00128440Phase 2
High Dose Trial in COPD
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6